Mridul Singh Sengar

Mridul Singh Sengar

Auto-generated profile, based on publicly available information

Mridul Singh Sengar

Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2025 in Current Drug Discovery Technologies
Verified
Journal Article
Closed access
PDF file
SSShristi Singh
Shristi Singh
NKNiranjan Kaushik
Niranjan Kaushik
APAjita Paliwal
Ajita Paliwal
MSMridul Singh Sengar
Mridul Singh Sengar
DPDeepika Paliwal
Deepika Paliwal
Coumarins, naturally occurring benzopyrones, have garnered significant attention due to their diverse pharmacological activities and therapeutic potential. Derived from natural sources and synthetic routes such as the Perkin and Pechmann reactions, these compounds exhibit a broad spectrum of biological activities, including antioxidant, anti-inflammatory, antimicrobial, anticancer, antidiabetic, and neuroprotective effects. The structure-activity relationship of coumarins highlights the critical role of substitutions at specific positions on the benzopyrone ring, enhancing their efficacy and selectivity. Notable applications include anticancer activities, with coumarin derivatives inhibiting tumor growth and inducing apoptosis in breast cancer and melanoma cells, and neuroprotection, particularly in Alzheimer's and Parkinson’s diseases, through acetylcholinesterase inhibition and β- amyloid modulation. Additionally, coumarins show promise in combating drug-resistant pathogens and oxidative stress. Despite their potential, challenges such as toxicity and bioavailability remain. Future research should focus on optimizing coumarin scaffolds and advancing clinical evaluations to establish their role as next-generation therapeutic agents.

10 May 2024
Verified
Book Chapter
Closed access
KRKalpana Pravin Rahate
Kalpana Pravin Rahate
MSMridul Singh Sengar
Mridul Singh Sengar
SPSakshi Patel
Sakshi Patel
The aim of this chapter is to introduce and discuss on new approaches to machine learning (ML) and deep learning (DL) in the context of medical image analysis. This includes new applications, structures, and algorithms. Additionally, to assess the precision with which DL algorithms detect disease in medical imaging. AI is heavily used in imaging in medicine. Numerous diagnostic activities, including the early identification and categorization of illnesses via the use of MRIs, CT scans, and other medical imaging, have shown the benefits of machine learning and deep learning algorithms. They make it easier to identify flaws, accurately segment organs, and locate malignancies, which speeds up and improves the accuracy of patient diagnosis. Since several review papers have evaluated the contributions of deep learning imaging methods and medical image analysis, this chapter specifically focuses on the assessment and summary of contributions from the Med AI.

1 November 2025 in Current Drug Discovery Technologies
Verified
Journal Article
Closed access
PDF file
MSMridul Singh Sengar
Mridul Singh Sengar
KRKalpana Rahate
Kalpana Rahate
MVMegha Verma
Megha Verma
Microbial infections continue to pose significant threats to global health, necessitating the development of innovative therapeutic strategies. One promising avenue is the use of protease inhibitors, with darunavir (DRV) emerging as a potent candidate in the field. Designed to combat resistance to standard HIV therapy, DRV is a second-generation protease inhibitor. Regarding microbial infections, this study sheds light on the internal processes behind the impact of DRV within cells. Novel protease inhibitor DRV targets essential proteolytic enzymes that are essential for microbial survival and growth in order to achieve its antimicrobial actions. By interfering with the proteolytic digestion of important microbial proteins, its inhibitory effect prevents infectious particles from being assembled and maturing. DRV is a viable treatment option for microbial infections as its selective suppression reduces the possibility of off-target consequences. DRV efficiently penetrates the intracellular milieu of host cells, where it prevents the proteolytic cleavage of vital viral and bacterial proteins, hence combating pathogenic infections. Microbial infections may be treated in a variety of ways using DRV as it disrupts the cycle of pathogen reproduction. The present review explores the molecular principles behind the effectiveness of DRV against microbial infections, emphasizing the drug's ability to fight a wide range of pathogens. The comprehension of the intracellular activity of DRV is promising for the creation of novel treatment approaches, providing encouragement in the continuous fight against microbial diseases.

24 September 2025 in Current Protein & Peptide Science
Verified
Journal Article
Closed access
SSShristi Singh
Shristi Singh
APAjita Paliwal
Ajita Paliwal
NKNiranjan Kaushik
Niranjan Kaushik
MSMridul Singh Senger
Mridul Singh Senger
SNSweta Negi
Sweta Negi
Protein kinase inhibitors (PKIs) are medicinal substances that target enzymes essential to vital cellular functions by controlling kinase activity. PKIs are being considered as targeted therapeutics to disrupt carcinogenic pathways since dysregulated kinase signalling is a hallmark of cancer. According to their binding mechanisms, PKIs are structurally categorised as follows: Type I inhibitors bind ATP competitively, Type II inhibitors target inactive kinase conformations, Type III inhibitors act through allosteric modulation, Type IV inhibitors operate independently of ATP, and Type V inhibitors, also referred to as covalent inhibitors, create irreversible bonds with target residues. PKIs have shown promise as a treatment for a number of malignancies, including leukemia, melanoma, lung, breast, and kidney cancers. While HER2-targeted PKIs have greatly improved results in breast cancer, targeting EGFR and ALK mutations has enhanced the treatment of lung cancer. Treatments for melanoma target BRAF and MEK inhibitors, while those for renal cell carcinoma concentrate on VEGF and mTOR pathways. Tyrosine kinase inhibitors have made significant strides in treating chronic myeloid leukemia, improving remission rates. Notwithstanding these achievements, resistance mechanisms still pose a threat to the efficacy of treatment, highlighting the necessity of continued investigation into next-generation PKIs and combination approaches to improve clinical outcomes for a range of cancer types. This article provides a comprehensive review of recent advancements in PKI research, including their mechanisms, therapeutic applications, and strategies to overcome drug resistance.

7 January 2026 in Current Organic Chemistry
Verified
Journal Article
Closed access
MSMridul Singh Sengar
Mridul Singh Sengar
NKNiranjan Kaushik
Niranjan Kaushik
APAjita Paliwal
Ajita Paliwal
SSShristi Singh
Shristi Singh
DPDeepika Paliwal
Deepika Paliwal
A naturally occurring xanthine derivative, theobromine has garnered considerable attention due to its broad range of biological activities and potential medical applications. In recent decades, theobromine chemistry has garnered considerable attention due to its numerous biological applications. The present study reports on several methods for synthesizing theobromine derivatives and their anticancer activity. Numerous biological properties, including antioxidant, anti-tumor, anti-inflammatory, bronchodilator, cardiovascular, and antibacterial properties, are provided by theobromine and its derivatives, which are members of the nitrogen-containing heterocycle family. Our findings highlight the therapeutic potential of theobromine as an anticancer agent. In addition to compiling the literature on theobromine's anticancer activity as reported by researchers, this study aims to highlight the most recent advancements regarding theobromine and provide a comprehensive understanding of theobromine, thereby opening the door for future research and therapeutic improvements.